Insider Buying: Shire PLC (SHP) Insider Buys 165 Shares of Stock

Shire PLC (LON:SHP) insider Dominic Blakemore purchased 165 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The stock was bought at an average price of GBX 3,790 ($51.40) per share, for a total transaction of £6,253.50 ($8,480.47).

Shire PLC (LON:SHP) traded down GBX 13.50 ($0.18) during midday trading on Thursday, reaching GBX 3,647.50 ($49.46). The company had a trading volume of 2,147,544 shares, compared to its average volume of 2,240,000. The stock has a market cap of $33,270.00 and a PE ratio of 2,784.35. Shire PLC has a one year low of GBX 3,435.50 ($46.59) and a one year high of GBX 5,067 ($68.71).

Several equities analysts have commented on the company. Deutsche Bank reissued a “buy” rating and set a GBX 5,000 ($67.81) price objective on shares of Shire in a research report on Thursday. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Shire in a research report on Wednesday. Citigroup reaffirmed a “buy” rating and issued a GBX 5,500 ($74.59) price target on shares of Shire in a research report on Friday, January 5th. Liberum Capital lowered Shire to a “hold” rating and lowered their price target for the stock from GBX 4,200 ($56.96) to GBX 4,100 ($55.60) in a research report on Wednesday, December 20th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a GBX 5,700 ($77.30) price target on shares of Shire in a research report on Friday, December 1st. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Shire has a consensus rating of “Buy” and an average price target of GBX 5,152.94 ($69.88).

ILLEGAL ACTIVITY NOTICE: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with's FREE daily email newsletter.

Leave a Reply